Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women

[1]  N. Hacker,et al.  Hormone replacement therapy and risk of epithelial ovarian cancer , 1999, British Journal of Cancer.

[2]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[3]  V. Beral,et al.  Hormonal therapy for menopause and ovarian cancer in a collaborative re‐analysis of European studies , 1999, International journal of cancer.

[4]  M. Thun,et al.  Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA , 1998, The Lancet.

[5]  K. Kerlikowske,et al.  HORMONE REPLACEMENT THERAPY AND THE RISK OF EPITHELIAL OVARIAN CARCINOMA: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[6]  H. Risch.  Estrogen replacement therapy and risk of epithelial ovarian cancer. , 1996, Gynecologic oncology.

[7]  C. Longcope,et al.  Serum gonadotropins and steroid hormones and the development of ovarian cancer. , 1995, JAMA.

[8]  N. Davidson.  Hormone-replacement therapy--breast versus heart versus bone. , 1995, The New England journal of medicine.

[9]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[10]  M. Thun,et al.  Estrogen replacement therapy and fatal ovarian cancer. , 1995, American journal of epidemiology.

[11]  D. Wysowski,et al.  Use of Menopausal Estrogens and Medroxyprogesterone in the United States, 1982–1992 , 1995, Obstetrics and gynecology.

[12]  C. la Vecchia,et al.  Estrogen replacement therapy and ovarian cancer risk , 1994, International journal of cancer.

[13]  T. Hamilton,et al.  Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells , 1994, Molecular and Cellular Endocrinology.

[14]  S. Thacker,et al.  Relative risks and benefits of long‐term estrogen replacement therapy: A decision analysis , 1994, Obstetrics and gynecology.

[15]  D. Trichopoulos,et al.  Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer , 1993, International journal of cancer.

[16]  A S Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[17]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[18]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[19]  S. Shapiro,et al.  Noncontraceptive estrogen use and epithelial ovarian cancer. , 1989, American journal of epidemiology.

[20]  V. Beral,et al.  Risk factors for ovarian cancer: a case-control study. , 1989, British Journal of Cancer.

[21]  N. Weiss,et al.  Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. , 1988, Cancer research.

[22]  P. Hartge,et al.  Menopause and ovarian cancer. , 1988, American journal of epidemiology.

[23]  L. Garfinkel,et al.  Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. , 1986, Journal of the National Cancer Institute.

[24]  D. Kennedy,et al.  Noncontraceptive estrogens and progestins: use patterns over time. , 1985, Obstetrics and gynecology.

[25]  N. Day,et al.  The epidemiology of ovarian cancer in Greece: a case-control study. , 1984, European journal of cancer & clinical oncology.

[26]  D. Cramer,et al.  Determinants of ovarian cancer risk. I. Reproductive experiences and family history. , 1983, Journal of the National Cancer Institute.

[27]  D. Cramer,et al.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.

[28]  J. Kelsey,et al.  An epidemiologic study of epithelial carcinoma of the ovary. , 1981, American journal of epidemiology.

[29]  W. O'Fallon,et al.  Ovarian cancer. Incidence and case‐control study , 1979, Cancer.

[30]  L. Wallentin,et al.  SERUM FSH, LH AND OESTRONE LEVELS IN POSTMENOPAUSAL PATIENTS ON OESTROGEN THERAPY , 1978, British journal of obstetrics and gynaecology.

[31]  L. Gray,et al.  STILBŒSTROL (DIETHYLSTILBESTROL) AND THE RISK OF OVARIAN CANCER , 1977, The Lancet.

[32]  H. Ziel,et al.  Increased risk of endometrial carcinoma among users of conjugated estrogens. , 1975, The New England journal of medicine.

[33]  D. Thompson,et al.  Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.

[34]  P. Wingo,et al.  Estrogen Therapy and the Risk of Breast, Ovarian, and Endometrial Cancer , 1986 .

[35]  S. E. Dietert,et al.  Noncontraceptive estrogen use and the occurrence of ovarian cancer. , 1982, Journal of the National Cancer Institute.